Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center

Aim:Medullary thyroid carcinoma (MTC) originating from parafollicular C cells is a sporadic endocrine tumor. A unique aspect of the disease is that it is 25% familial and component of multiple endocrine neoplasia 2 syndromes. Surgical resection has curative potential in the early stages. Systemic tr...

Full description

Bibliographic Details
Published in:	Namık Kemal Tıp Dergisi
Main Authors:	Ferhat FERHATOĞLU, Nail PAKSOY, Mert BAŞARAN
Format:	Article
Language:	English
Published:	Tekirdağ Namık Kemal University 2022-12-01
Subjects:	survival vandetanib cancer progression thyroid
Online Access:	http://namikkemalmedj.com/archives/archive-detail/article-preview/systemic-treatment-outcomes-of-progressive-medulla/57551

Similar Items

Disseminated medullary thyroid carcinoma. Optimal approach to treatment
by: I. S. Romanov, et al.
Published: (2019-01-01)

Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)
by: I. S. Romanov, et al.
Published: (2020-07-01)

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report
by: А. М. Mudunov, et al.
Published: (2019-10-01)

Treatment Outcomes and Toxicities of Multiple Tyrosin Kinase Inhibitors for Metastatic Medullary Thyroid Cancer: A Case Series
by: Marilda Mormando, et al.
Published: (2024-12-01)

Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations
by: Begümhan Demir Gündoğan, et al.
Published: (2021-09-01)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
by: Fallahi P, et al.
Published: (2019-08-01)

Rare complications of multikinase inhibitor treatment
by: Fabián Pitoia, et al.

Design of new drugs for medullary thyroid carcinoma
by: Yanqing Li, et al.
Published: (2022-12-01)

Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration
by: Silvia Martina Ferrari, et al.
Published: (2018-12-01)

Hashimoto's Thyroiditis and Medullary Carcinoma of Thyroid
by: Senjuti Dasgupta, et al.
Published: (2014-06-01)

Selpercatinib – a new option for a precision approach to the treatment of medullary thyroid cancer
by: A. K. Plugar, et al.
Published: (2024-12-01)

Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01)

A Unique Case of Medullary Thyroid Carcinoma in the Background of Hashimoto's Thyroiditis
by: Allahdad Khan, et al.
Published: (2025-04-01)

Oncogenic and drug-sensitive RET mutations in human epithelial ovarian cancer
by: Luyao Guan, et al.
Published: (2020-03-01)

Distinct Impacts of Clinicopathological and Mutational Profiles on Long-Term Survival and Recurrence in Medullary Thyroid Carcinoma
by: Moon Young Oh, et al.
Published: (2024-12-01)

Thirty synchronous medullary and papillary thyroid carcinomas
by: Daqi Zhang, et al.
Published: (2023-03-01)

Development and validation of a nomogram based on stromal score to predict progression‐free survival of patients with papillary thyroid carcinoma
by: Jiajia Tang, et al.
Published: (2021-08-01)

Medullary thyroid carcinoma of unknown primary origin with synchronous finding of papillary thyroid carcinoma
by: Andrzej R. Hellmann, et al.
Published: (2020-04-01)

Clinicopathological features and outcomes in patients with concurrent medullary and papillary thyroid carcinoma
by: Ruonan Sun, et al.
Published: (2025-08-01)

Changes of biochemical factors and the effect on recurrence of medullary thyroid carcinoma after surgery
by: Fengli Guo, et al.
Published: (2024-04-01)

Vandetanib as a prospective anti-inflammatory and anti-contractile agent in asthma
by: Xiaoyue Zeng, et al.
Published: (2024-05-01)

Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma
by: Wenliang Yue, et al.
Published: (2022-11-01)

RET splice site variants in medullary thyroid carcinoma
by: Daryoush Saeed-Vafa, et al.
Published: (2024-03-01)

Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass
by: LI Rui, LIU Zhuoran, YAN Jiqi
Published: (2022-06-01)

Metachronous Follicular Variant of Papillary Thyroid Microcarcinoma in a Case of Medullary Carcinoma Thyroid
by: Neelam Sood, et al.
Published: (2016-07-01)

Simultaneous presentation of parathyroid adenoma and papillary and medullary thyroid carcinoma
by: Luis R. Albavera-Giles, et al.
Published: (2025-04-01)

Simultaneous Occurrence of Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma: A Case Series with Literature Review
by: Poupak Fallahi, et al.
Published: (2023-11-01)

Critically evaluated key points on hereditary medullary thyroid carcinoma
by: Daqi Zhang, et al.
Published: (2024-06-01)

Cytologic aspects of an interesting case of medullary thyroid carcinoma coexisting with Hashimoto′s thyroiditis
by: Bidish K Patel, et al.
Published: (2016-01-01)

Efficacy of external beam radiotherapy and targeted therapy with vandenanib in patients with inoperable and progressive medullary thyroid cancer
by: A. D. Kaprin, et al.
Published: (2018-11-01)

Thyroid Collision Tumors: The Presence of the Medullary Thyroid Carcinoma Component Negatively Influences the Prognosis
by: Ion Negura, et al.
Published: (2023-01-01)

Diagnosis and treatment of medullary thyroid carcinoma-an update
by: CHEN Chengkun, GUO Bomin, DENG Xianzhao, WU Bo, FAN Youben
Published: (2022-06-01)

Measuring discrepancies between simple medullary and synchronous medullary/papillary thyroid carcinomas: a comparative cross-sectional study
by: Daqi Zhang, et al.
Published: (2024-01-01)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
by: Abdul Qadir, MPhil, et al.
Published: (2023-10-01)

The Establishment and Verification of a Nomogram Model for Predicting the Overall Survival of Medullary Thyroid Carcinoma: An Analysis Based on the SEER Database
by: Wankun Wang, et al.
Published: (2023-12-01)

Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review)
by: E. V. Borodavina, et al.
Published: (2025-03-01)

Update of pathology in medullary thyroid carcinoma
by: LIU Zhiyan, YU Yaling, KAKUDO Kennichi
Published: (2023-11-01)

Mouse models of follicular and papillary thyroid cancer progression
by: Marika A. Russo, et al.
Published: (2012-01-01)

Anaplastic thyroid carcinoma case series
by: Nadire Küçüköztaş, et al.
Published: (2024-01-01)

Long-term survival outcomes of systemic therapy in patients with isolated and mixed medullary thyroid cancer
by: Manal S. Fawzy, et al.
Published: (2024-07-01)